I 

119TH CONGRESS 

1ST SESSION H. R. 27 

To amend the Controlled Substances Act with respect to the scheduling 

of fentanyl-related substances, and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

JANUARY 3, 2025 

Mr. GRIFFITH (for himself, Mr. LATTA, Mr. GUTHRIE, Mr. BILIRAKIS, Mr. 

HUDSON, Mr. CARTER of Georgia, Mr. PALMER, Mr. DUNN of Florida, 

Mr. CRENSHAW, Mr. JOYCE of Pennsylvania, Mr. PFLUGER, Mrs. 

HARSHBARGER, Mrs. CAMMACK, Mrs. MILLER-MEEKS, Mr. WOMACK, 

Mr. BUCHANAN, Mrs. MILLER of West Virginia, Mr. MOOLENAAR, Mr. 

BOST, Mr. EVANS of Colorado, Mr. FITZGERALD, Mr. LANGWORTHY, Mr. 

CLINE, Mr. MEUSER, Mr. VAN DREW, Mr. FEENSTRA, and Mr. NUNN

of Iowa) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on 

the Judiciary, for a period to be subsequently determined by the Speaker, 

in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned 

A BILL 

To amend the Controlled Substances Act with respect to 

the scheduling of fentanyl-related substances, and for 

other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Halt All Lethal Traf5 ficking of Fentanyl Act’’ or the ‘‘HALT Fentanyl Act’’. 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
2 

•HR 27 IH

1 SEC. 2. CLASS SCHEDULING OF FENTANYL-RELATED SUB2 STANCES. 

3 Section 202(c) of the Controlled Substances Act (21 

4 U.S.C. 812(c)) is amended by adding at the end of sched5 ule I the following: 

6 ‘‘(e)(1) Unless specifically exempted or unless listed 

7 in another schedule, any material, compound, mixture, or 

8 preparation which contains any quantity of a fentanyl-re9 lated substance, or which contains the salts, isomers, and 

10 salts of isomers of a fentanyl-related substance whenever 

11 the existence of such salts, isomers, and salts of isomers 

12 is possible within the specific chemical designation. 

13 ‘‘(2) For purposes of paragraph (1), except as 

14 provided in paragraph (3), the term ‘fentanyl-related 

15 substance’ means any substance that is structurally 

16 related to fentanyl by 1 or more of the following 

17 modifications: 

18 ‘‘(A) By replacement of the phenyl portion 

19 of the phenethyl group by any monocycle, 

20 whether or not further substituted in or on the 

21 monocycle. 

22 ‘‘(B) By substitution in or on the 

23 phenethyl group with alkyl, alkenyl, alkoxyl, 

24 hydroxyl, halo, haloalkyl, amino, or nitro 

25 groups. 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
3 

•HR 27 IH

1 ‘‘(C) By substitution in or on the piper2 idine ring with alkyl, alkenyl, alkoxyl, ester, 

3 ether, hydroxyl, halo, haloalkyl, amino, or nitro 

4 groups. 

5 ‘‘(D) By replacement of the aniline ring 

6 with any aromatic monocycle whether or not 

7 further substituted in or on the aromatic mono8 cycle. 

9 ‘‘(E) By replacement of the N–propionyl 

10 group with another acyl group. 

11 ‘‘(3) A substance that satisfies the definition of 

12 the term ‘fentanyl-related substance’ in paragraph 

13 (2) shall nonetheless not be treated as a fentanyl-re14 lated substance subject to this schedule if the sub15 stance— 

16 ‘‘(A) is controlled by action of the Attorney 

17 General under section 201; or 

18 ‘‘(B) is otherwise expressly listed in a 

19 schedule other than this schedule. 

20 ‘‘(4)(A) The Attorney General may by order 

21 publish in the Federal Register a list of substances 

22 that satisfy the definition of the term ‘fentanyl-re23 lated substance’ in paragraph (2). 

24 ‘‘(B) The absence of a substance from a 

25 list published under subparagraph (A) does not 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
4 

•HR 27 IH

1 negate the control status of the substance 

2 under this schedule if the substance satisfies 

3 the definition of the term ‘fentanyl-related sub4 stance’ in paragraph (2).’’. 

5 SEC. 3. REGISTRATION REQUIREMENTS RELATED TO RE6 SEARCH. 

7 (a) ALTERNATIVE REGISTRATION PROCESS FOR

8 SCHEDULE I RESEARCH.—Section 303 of the Controlled 

9 Substances Act (21 U.S.C. 823) is amended— 

10 (1) by redesignating the second subsection (l) 

11 (relating to required training for prescribers) as sub12 section (m); and 

13 (2) by adding at the end the following: 

14 ‘‘(n) SPECIAL PROVISIONS FOR PRACTITIONERS

15 CONDUCTING CERTAIN RESEARCH WITH SCHEDULE I 

16 CONTROLLED SUBSTANCES.— 

17 ‘‘(1) IN GENERAL.—Notwithstanding subsection 

18 (g), a practitioner may conduct research described in 

19 paragraph (2) of this subsection with 1 or more 

20 schedule I substances in accordance with subpara21 graph (A) or (B) of paragraph (3) of this sub22 section. 

23 ‘‘(2) RESEARCH SUBJECT TO EXPEDITED PRO24 CEDURES.—Research described in this paragraph is 

25 research that— 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
5 

•HR 27 IH

1 ‘‘(A) is with respect to a drug that is the 

2 subject of an investigational use exemption 

3 under section 505(i) of the Federal Food, Drug, 

4 and Cosmetic Act; or 

5 ‘‘(B) is— 

6 ‘‘(i) conducted by the Department of 

7 Health and Human Services, the Depart8 ment of Defense, or the Department of 

9 Veterans Affairs; or 

10 ‘‘(ii) funded partly or entirely by a 

11 grant, contract, cooperative agreement, or 

12 other transaction from the Department of 

13 Health and Human Services, the Depart14 ment of Defense, or the Department of 

15 Veterans Affairs. 

16 ‘‘(3) EXPEDITED PROCEDURES.— 

17 ‘‘(A) RESEARCHER WITH A CURRENT

18 SCHEDULE I OR II RESEARCH REGISTRATION.— 

19 ‘‘(i) IN GENERAL.—If a practitioner is 

20 registered to conduct research with a con21 trolled substance in schedule I or II, the 

22 practitioner may conduct research under 

23 this subsection on and after the date that 

24 is 30 days after the date on which the 

25 practitioner sends a notice to the Attorney 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
6 

•HR 27 IH

1 General containing the following informa2 tion, with respect to each substance with 

3 which the practitioner will conduct the re4 search: 

5 ‘‘(I) The chemical name of the 

6 substance. 

7 ‘‘(II) The quantity of the sub8 stance to be used in the research. 

9 ‘‘(III) Demonstration that the re10 search is in the category described in 

11 paragraph (2), which demonstration 

12 may be satisfied— 

13 ‘‘(aa) in the case of a grant, 

14 contract, cooperative agreement, 

15 or other transaction, or intra16 mural research project, by identi17 fying the sponsoring agency and 

18 supplying the number of the 

19 grant, contract, cooperative 

20 agreement, other transaction, or 

21 project; or 

22 ‘‘(bb) in the case of an ap23 plication under section 505(i) of 

24 the Federal Food, Drug, and 

25 Cosmetic Act, by supplying the 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
7 

•HR 27 IH

1 application number and the spon2 sor of record on the application. 

3 ‘‘(IV) Demonstration that the re4 searcher is authorized to conduct re5 search with respect to the substance 

6 under the laws of the State in which 

7 the research will take place. 

8 ‘‘(ii) VERIFICATION OF INFORMATION

9 BY HHS OR VA.—Upon request from the 

10 Attorney General, the Secretary of Health 

11 and Human Services, the Department of 

12 Defense, or the Secretary of Veterans Af13 fairs, as appropriate, shall verify informa14 tion submitted by an applicant under 

15 clause (i)(III). 

16 ‘‘(B) RESEARCHER WITHOUT A CURRENT

17 SCHEDULE I OR II RESEARCH REGISTRATION.— 

18 ‘‘(i) IN GENERAL.—If a practitioner is 

19 not registered to conduct research with a 

20 controlled substance in schedule I or II, 

21 the practitioner may send a notice to the 

22 Attorney General containing the informa23 tion listed in subparagraph (A)(i), with re24 spect to each substance with which the 

25 practitioner will conduct the research. 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
8 

•HR 27 IH

1 ‘‘(ii) ATTORNEY GENERAL ACTION.— 

2 The Attorney General shall— 

3 ‘‘(I) treat notice received under 

4 clause (i) as a sufficient application 

5 for a research registration; and 

6 ‘‘(II) not later than 45 days of 

7 receiving such a notice that contains 

8 all information required under sub9 paragraph (A)(i)— 

10 ‘‘(aa) register the applicant; 

11 or 

12 ‘‘(bb) serve an order to show 

13 cause upon the applicant in ac14 cordance with section 304(c). 

15 ‘‘(4) ELECTRONIC SUBMISSIONS.—The Attorney 

16 General shall provide a means to permit a practi17 tioner to submit a notification under paragraph (3) 

18 electronically. 

19 ‘‘(5) LIMITATION ON AMOUNTS.—A practitioner 

20 conducting research with a schedule I substance 

21 under this subsection may only possess the amounts 

22 of schedule I substance identified in— 

23 ‘‘(A) the notification to the Attorney Gen24 eral under paragraph (3); or 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
9 

•HR 27 IH

1 ‘‘(B) a supplemental notification that the 

2 practitioner may send if the practitioner needs 

3 additional amounts for the research, which sup4 plemental notification shall include— 

5 ‘‘(i) the name of the practitioner; 

6 ‘‘(ii) the additional quantity needed of 

7 the substance; and 

8 ‘‘(iii) an attestation that the research 

9 to be conducted with the substance is con10 sistent with the scope of the research that 

11 was the subject of the notification under 

12 paragraph (3). 

13 ‘‘(6) IMPORTATION AND EXPORTATION RE14 QUIREMENTS NOT AFFECTED.—Nothing in this sub15 section alters the requirements of part A of title III, 

16 regarding the importation and exportation of con17 trolled substances. 

18 ‘‘(7) INSPECTOR GENERAL REPORT.—Not later 

19 than 1 year after the date of enactment of this Act, 

20 the Inspector General of the Department of Justice 

21 shall complete a study, and submit a report thereon, 

22 about research described in paragraph (2) of this 

23 subsection with fentanyl.’’. 

24 (b) SEPARATE REGISTRATIONS NOT REQUIRED FOR

25 ADDITIONAL RESEARCHER IN SAME INSTITUTION.— 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
10 

•HR 27 IH

1 (1) IN GENERAL.—Section 302(c) of the Con2 trolled Substances Act (21 U.S.C. 822(c)) is amend3 ed by adding at the end the following: 

4 ‘‘(4) An agent or employee of a research insti5 tution that is conducting research with a controlled 

6 substance if— 

7 ‘‘(A) the agent or employee is acting with8 in the scope of the professional practice of the 

9 agent or employee; 

10 ‘‘(B) another agent or employee of the in11 stitution is registered to conduct research with 

12 a controlled substance in the same schedule; 

13 ‘‘(C) the researcher who is so registered— 

14 ‘‘(i) informs the Attorney General of 

15 the name, position title, and employing in16 stitution of the agent or employee who is 

17 not separately registered; 

18 ‘‘(ii) authorizes that agent or em19 ployee to perform research under the reg20 istration of the registered researcher; and 

21 ‘‘(iii) affirms that any act taken by 

22 that agent or employee involving a con23 trolled substance shall be attributable to 

24 the registered researcher, as if the re25 searcher had directly committed the act, 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
11 

•HR 27 IH

1 for purposes of any proceeding under sec2 tion 304(a) to suspend or revoke the reg3 istration of the registered researcher; and 

4 ‘‘(D) the Attorney General does not, within 

5 30 days of receiving the information, authoriza6 tion, and affirmation described in subparagraph 

7 (C), refuse, for a reason listed in section 

8 304(a), to allow the agent or employee to pos9 sess the substance without a separate registra10 tion.’’. 

11 (2) TECHNICAL CORRECTION.—Section 

12 302(c)(3) of the Controlled Substances Act (21 

13 U.S.C. 822(c)(3)) is amended by striking ‘‘(25)’’ 

14 and inserting ‘‘(27)’’. 

15 (c) SINGLE REGISTRATION FOR RELATED RESEARCH

16 SITES.—Section 302(e) of the Controlled Substances Act 

17 (21 U.S.C. 822(e)) is amended by adding at the end the 

18 following: 

19 ‘‘(4)(A) Notwithstanding paragraph (1), a per20 son registered to conduct research with a controlled 

21 substance under section 303(f) may conduct the re22 search under a single registration if— 

23 ‘‘(i) the research occurs exclusively on 

24 sites all of which are— 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
12 

•HR 27 IH

1 ‘‘(I) within the same city or 

2 county; and 

3 ‘‘(II) under the control of the 

4 same institution, organization, or 

5 agency; and 

6 ‘‘(ii) before commencing the research, 

7 the researcher notifies the Attorney Gen8 eral of each site where— 

9 ‘‘(I) the research will be con10 ducted; or 

11 ‘‘(II) the controlled substance 

12 will be stored or administered. 

13 ‘‘(B) A site described in subparagraph (A) 

14 shall be included in a registration described in 

15 that subparagraph only if the researcher has 

16 notified the Attorney General of the site— 

17 ‘‘(i) in the application for the registra18 tion; or 

19 ‘‘(ii) before the research is conducted, 

20 or before the controlled substance is stored 

21 or administered, at the site. 

22 ‘‘(C) The Attorney General may, in con23 sultation with the Secretary, issue regulations 

24 addressing, with respect to research sites de25 scribed in subparagraph (A)— 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
13 

•HR 27 IH

1 ‘‘(i) the manner in which controlled 

2 substances may be delivered to the re3 search sites; 

4 ‘‘(ii) the storage and security of con5 trolled substances at the research sites; 

6 ‘‘(iii) the maintenance of records for 

7 the research sites; and 

8 ‘‘(iv) any other matters necessary to 

9 ensure effective controls against diversion 

10 at the research sites.’’. 

11 (d) NEW INSPECTION NOT REQUIRED IN CERTAIN

12 SITUATIONS.—Section 302(f) of the Controlled Sub13 stances Act (21 U.S.C. 822(f)) is amended— 

14 (1) by striking ‘‘(f) The’’ and inserting ‘‘(f)(1) 

15 The’’; and 

16 (2) by adding at the end the following: 

17 ‘‘(2)(A) If a person is registered to conduct re18 search with a controlled substance and applies for a 

19 registration, or for a modification of a registration, 

20 to conduct research with a second controlled sub21 stance that is in the same schedule as the first con22 trolled substance, or is in a schedule with a higher 

23 numerical designation than the schedule of the first 

24 controlled substance, a new inspection by the AttorVerDate Sep 11 2014 20:28 Jan 27, 2025 Jkt 059200 PO 00000 Frm 00013 Fmt 6652 Sfmt 6201 E:\BILLS\H27.IH H27

kjohnson on DSK7ZCZBW3PROD with $$_JOB
14 

•HR 27 IH

1 ney General of the registered location is not re2 quired. 

3 ‘‘(B) Nothing in subparagraph (A) shall pro4 hibit the Attorney General from conducting an in5 spection that the Attorney General determines nec6 essary to ensure that a registrant maintains effective 

7 controls against diversion.’’. 

8 (e) CONTINUATION OF RESEARCH ON SUBSTANCES

9 NEWLY ADDED TO SCHEDULE I.—Section 302 of the 

10 Controlled Substances Act (21 U.S.C. 822) is amended 

11 by adding at the end the following: 

12 ‘‘(h) CONTINUATION OF RESEARCH ON SUBSTANCES

13 NEWLY ADDED TO SCHEDULE I.—If a person is con14 ducting research on a substance when the substance is 

15 added to schedule I, and the person is already registered 

16 to conduct research with a controlled substance in sched17 ule I— 

18 ‘‘(1) not later than 90 days after the scheduling 

19 of the newly scheduled substance, the person shall 

20 submit a completed application for registration or 

21 modification of existing registration, to conduct re22 search on the substance, in accordance with regula23 tions issued by the Attorney General for purposes of 

24 this paragraph; 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
15 

•HR 27 IH

1 ‘‘(2) the person may, notwithstanding sub2 sections (a) and (b), continue to conduct the re3 search on the substance until— 

4 ‘‘(A) the person withdraws the application 

5 described in paragraph (1) of this subsection; 

6 or 

7 ‘‘(B) the Attorney General serves on the 

8 person an order to show cause proposing the 

9 denial of the application under section 304(c); 

10 ‘‘(3) if the Attorney General serves an order to 

11 show cause as described in paragraph (2)(B) and 

12 the person requests a hearing, the hearing shall be 

13 held on an expedited basis and not later than 45 

14 days after the request is made, except that the hear15 ing may be held at a later time if so requested by 

16 the person; and 

17 ‘‘(4) if the person sends a copy of the applica18 tion described in paragraph (1) to a manufacturer or 

19 distributor of the substance, receipt of the copy by 

20 the manufacturer or distributor shall constitute suf21 ficient evidence that the person is authorized to re22 ceive the substance.’’. 

23 (f) TREATMENT OF CERTAIN MANUFACTURING AC24 TIVITIES AS COINCIDENT TO RESEARCH.—Section 302 of 

25 the Controlled Substances Act (21 U.S.C. 822), as amendVerDate Sep 11 2014 20:28 Jan 27, 2025 Jkt 059200 PO 00000 Frm 00015 Fmt 6652 Sfmt 6201 E:\BILLS\H27.IH H27

kjohnson on DSK7ZCZBW3PROD with $$_JOB
16 

•HR 27 IH

1 ed by subsection (e), is amended by adding at the end 

2 the following: 

3 ‘‘(i) TREATMENT OF CERTAIN MANUFACTURING AC4 TIVITIES AS COINCIDENT TO RESEARCH.— 

5 ‘‘(1) IN GENERAL.—Except as provided in para6 graph (3), a person who is registered to perform re7 search on a controlled substance may perform manu8 facturing activities with small quantities of that sub9 stance, including activities described in paragraph 

10 (2), without being required to obtain a manufac11 turing registration, if— 

12 ‘‘(A) the activities are performed for the 

13 purpose of the research; and 

14 ‘‘(B) the activities and the quantities of 

15 the substance involved in the activities are stat16 ed in— 

17 ‘‘(i) a notification submitted to the 

18 Attorney General under section 303(l); 

19 ‘‘(ii) a research protocol filed with an 

20 application for registration approval under 

21 section 303(f); or 

22 ‘‘(iii) a notification to the Attorney 

23 General that includes— 

24 ‘‘(I) the name of the registrant; 

25 and 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
17 

•HR 27 IH

1 ‘‘(II) an attestation that the re2 search to be conducted with the small 

3 quantities of manufactured substance 

4 is consistent with the scope of the re5 search that is the basis for the reg6 istration. 

7 ‘‘(2) ACTIVITIES INCLUDED.—Activities per8 mitted under paragraph (1) include— 

9 ‘‘(A) processing the substance to create ex10 tracts, tinctures, oils, solutions, derivatives, or 

11 other forms of the substance consistent with— 

12 ‘‘(i) the information provided as part 

13 of a notification submitted to the Attorney 

14 General under section 303(l); or 

15 ‘‘(ii) a research protocol filed with an 

16 application for registration approval under 

17 section 303(f); and 

18 ‘‘(B) dosage form development studies per19 formed for the purpose of requesting an inves20 tigational new drug exemption under section 

21 505(i) of the Federal Food, Drug, and Cos22 metic Act (21 U.S.C. 355(i)). 

23 ‘‘(3) EXCEPTION REGARDING MARIHUANA.— 

24 The authority under paragraph (1) to manufacture 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
18 

•HR 27 IH

1 substances does not include the authority to grow 

2 marihuana.’’. 

3 (g) TRANSPARENCY REGARDING SPECIAL PROCE4 DURES.—Section 303 of the Controlled Substances Act 

5 (21 U.S.C. 823), as amended by subsection (a), is amend6 ed by adding at the end the following: 

7 ‘‘(o) TRANSPARENCY REGARDING SPECIAL PROCE8 DURES.— 

9 ‘‘(1) IN GENERAL.—If the Attorney General de10 termines, with respect to a controlled substance, that 

11 an application by a practitioner to conduct research 

12 with the substance should be considered under a 

13 process, or subject to criteria, different from the 

14 process or criteria applicable to applications to con15 duct research with other controlled substances in the 

16 same schedule, the Attorney General shall make 

17 public, including by posting on the website of the 

18 Drug Enforcement Administration— 

19 ‘‘(A) the identities of all substances for 

20 which such determinations have been made; 

21 ‘‘(B) the process and criteria that shall be 

22 applied to applications to conduct research with 

23 those substances; and 

24 ‘‘(C) how the process and criteria described 

25 in subparagraph (B) differ from the process 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
19 

•HR 27 IH

1 and criteria applicable to applications to con2 duct research with other controlled substances 

3 in the same schedule. 

4 ‘‘(2) TIMING OF POSTING.—The Attorney Gen5 eral shall make information described in paragraph 

6 (1) public upon making a determination described in 

7 that paragraph, regardless of whether a practitioner 

8 has submitted such an application at that time.’’. 

9 SEC. 4. TECHNICAL CORRECTION ON CONTROLLED SUB10 STANCES DISPENSING. 

11 Effective as if included in the enactment of Public 

12 Law 117–328— 

13 (1) section 1252(a) of division FF of Public 

14 Law 117–328 (136 Stat. 5681) is amended, in the 

15 matter being inserted into section 302(e) of the Con16 trolled Substances Act, by striking ‘‘303(g)’’ and in17 serting ‘‘303(h)’’; 

18 (2) section 1262 of division FF of Public Law 

19 117–328 (136 Stat. 5681) is amended— 

20 (A) in subsection (a)— 

21 (i) in the matter preceding paragraph 

22 (1), by striking ‘‘303(g)’’ and inserting 

23 ‘‘303(h)’’; 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
20 

•HR 27 IH

1 (ii) in the matter being stricken by 

2 subsection (a)(2), by striking ‘‘(g)(1)’’ and 

3 inserting ‘‘(h)(1)’’; and 

4 (iii) in the matter being inserted by 

5 subsection (a)(2), by striking ‘‘(g) Practi6 tioners’’ and inserting ‘‘(h) Practitioners’’; 

7 and 

8 (B) in subsection (b)— 

9 (i) in the matter being stricken by 

10 paragraph (1), by striking ‘‘303(g)(1)’’ 

11 and inserting ‘‘303(h)(1)’’; 

12 (ii) in the matter being inserted by 

13 paragraph (1), by striking ‘‘303(g)’’ and 

14 inserting ‘‘303(h)’’; 

15 (iii) in the matter being stricken by 

16 paragraph (2)(A), by striking ‘‘303(g)(2)’’ 

17 and inserting ‘‘303(h)(2)’’; 

18 (iv) in the matter being stricken by 

19 paragraph (3), by striking ‘‘303(g)(2)(B)’’ 

20 and inserting ‘‘303(h)(2)(B)’’; 

21 (v) in the matter being stricken by 

22 paragraph (5), by striking ‘‘303(g)’’ and 

23 inserting ‘‘303(h)’’; and 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
21 

•HR 27 IH

1 (vi) in the matter being stricken by 

2 paragraph (6), by striking ‘‘303(g)’’ and 

3 inserting ‘‘303(h)’’; and 

4 (3) section 1263(b) of division FF of Public 

5 Law 117–328 (136 Stat. 5685) is amended— 

6 (A) by striking ‘‘303(g)(2)’’ and inserting 

7 ‘‘303(h)(2)’’; and 

8 (B) by striking ‘‘(21 U.S.C. 823(g)(2))’’ 

9 and inserting ‘‘(21 U.S.C. 823(h)(2))’’. 

10 SEC. 5. RULEMAKING. 

11 (a) INTERIM FINAL RULES.—The Attorney Gen12 eral— 

13 (1) shall, not later than 6 months after the date 

14 of enactment of this Act, issue rules to implement 

15 this Act and the amendments made by this Act; and 

16 (2) may issue the rules under paragraph (1) as 

17 interim final rules. 

18 (b) PROCEDURE FOR FINAL RULE.— 

19 (1) EFFECTIVENESS OF INTERIM FINAL

20 RULES.—A rule issued by the Attorney General as 

21 an interim final rule under subsection (a) shall be22 come immediately effective as an interim final rule 

23 without requiring the Attorney General to dem24 onstrate good cause therefor, notwithstanding subVerDate Sep 11 2014 20:28 Jan 27, 2025 Jkt 059200 PO 00000 Frm 00021 Fmt 6652 Sfmt 6201 E:\BILLS\H27.IH H27

kjohnson on DSK7ZCZBW3PROD with $$_JOB
22 

•HR 27 IH

1 paragraph (B) of section 553(b) of title 5, United 

2 States Code. 

3 (2) OPPORTUNITY FOR COMMENT AND HEAR4 ING.—An interim final rule issued under subsection 

5 (a) shall give interested persons the opportunity to 

6 comment and to request a hearing. 

7 (3) FINAL RULE.—After the conclusion of such 

8 proceedings, the Attorney General shall issue a final 

9 rule to implement this Act and the amendments 

10 made by this Act in accordance with section 553 of 

11 title 5, United States Code. 

12 SEC. 6. PENALTIES. 

13 (a) IN GENERAL.—Section 401(b)(1) of the Con14 trolled Substances Act (21 U.S.C. 841(b)(1)) is amend15 ed— 

16 (1) in subparagraph (A)(vi), by inserting ‘‘or a 

17 fentanyl-related substance’’ after ‘‘any analogue of 

18 N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl] 

19 propanamide’’; and 

20 (2) in subparagraph (B)(vi), by inserting ‘‘or a 

21 fentanyl-related substance’’ after ‘‘any analogue of 

22 N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl] 

23 propanamide’’. 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
23 

•HR 27 IH

1 (b) IMPORTATION AND EXPORTATION.—Section 

2 1010(b) of the Controlled Substances Import and Export 

3 Act (21 U.S.C. 960(b)) is amended— 

4 (1) in paragraph (1)(F), by inserting ‘‘or a 

5 fentanyl-related substance’’ after ‘‘any analogue of 

6 N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl] 

7 propanamide’’; and 

8 (2) in paragraph (2)(F), by inserting ‘‘or a 

9 fentanyl-related substance’’ after ‘‘any analogue of 

10 N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl] 

11 propanamide’’. 

12 SEC. 7. APPLICABILITY; OTHER MATTERS. 

13 (a) IN GENERAL.—Irrespective of the date on which 

14 the rules required by section 4 are finalized, the amend15 ments made by this Act apply beginning as of the enact16 ment of this Act. 

17 (b) RULE OF CONSTRUCTION.—Nothing in the 

18 amendments made by this Act may be construed as evi19 dence that, in applying sections 401(b)(1) and 1010(b) of 

20 the Controlled Substances Act (21 U.S.C. 841(b)(1) and 

21 960(b)) with respect to conduct occurring before the date 

22 of the enactment of this Act, a fentanyl-related substance 

23 (as defined by such amendments) is not an analogue of 

24 N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl] 

25 propanamide. 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
24 

•HR 27 IH

1 (c) SENSE OF CONGRESS.—The Congress agrees with 

2 the interpretation of the Controlled Substances Act (21 

3 U.S.C. 801 et seq.) in United States v. McCray, 346 F. 

4 Supp. 3d 363 (2018). 

Æ 


kjohnson on DSK7ZCZBW3PROD with $$_JOB